Agilent Technologies Inc. (A) News
Filter A News Items
A News Results
|Loading, please wait...|
A News Highlights
- For A, its 30 day story count is now at 16.
- Over the past 22 days, the trend for A's stories per day has been choppy and unclear. It has oscillated between 1 and 5.
- PAY, EXAS and ILMN are the most mentioned tickers in articles about A.
Latest A News From Around the Web
Below are the latest news stories about AGILENT TECHNOLOGIES INC that investors may wish to consider to help them evaluate A as an investment opportunity.
With higher interest rates well into 2024, institutional money is likely to flow back into some of the best value stocks.
Just three Warren Buffett dividend stocks account for nearly half of all the dividend payments Berkshire Hathaway will receive in 2023.
These long-term stocks are essential for crafting a balanced portfolio that'll consistently generate high returns for decades.
Each time Buffett buys or sells a stock, it makes news headlines.
SANTA CLARA, Calif., September 20, 2023--Agilent Technologies, Inc. (NYSE: A) today announced that a quarterly dividend of 22.5 cents per share of common stock will be paid on Oct. 25, 2023, to all shareholders of record as of the close of business on Oct. 3, 2023.
Agilent Technologies, Inc. (NYSE: NYSE:A), a global leader in analytical and clinical laboratory technologies, has announced on Wednesday that a quarterly dividend of 22.5 cents per share of common stock will be paid to all shareholders of record as of the close of business on October 3, 2023. The dividend is scheduled for payment on October 25, 2023.
Agilent (A) collaborates with the National Cancer Centre Singapore to accelerate Asian-prevalent cancer research over the next two years.
Agilent and NCCS Sign Research Collaboration Agreement to Advance Singapore's Genomic Profiling on Asian-prevalent Cancers
Agilent Technologies Inc. (NYSE: A) recently signed a Research Collaboration Agreement (RCA) with the National Cancer Centre Singapore (NCCS) outlining their collaboration to accelerate translational cancer research on the genomic landscape of Asian-prevalent cancers over the next two years.
Despite his track record of success, the Oracle of Omaha is not immune from making poor investment decisions like the rest of us.
Unpacking the Growth and Competitive Edges of Agilent Technologies Inc (A)